Lung Cancer

Paul K. Paik, MD, discusses the clinical implications of tepotinib on the non–small cell lung cancer armamentarium.

Experts discuss how results from the ADAURA trial may influence treatment decisions in the adjuvant setting of non–small cell lung cancer (NSCLC).

Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Expert thought leaders in thoracic oncology share their experiences with EGFR-TKI combination strategies in patients with EGFR-mutated metastatic NSCLC.

Panelists reflect on barriers to obtaining tissue biopsies in patients with EGFR-mutated metastatic NSCLC and share insights into the importance of making treatment decisions based on molecular testing results.

David P. Mason, MD, discusses new neoadjuvant and adjuvant developments in the treatment of patients with non–small cell lung cancer, as well as what those data mean from a surgical perspective.

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Early detection of primary lung cancer using low-dose computed tomography screening was associated with a lower risk of brain metastases after PLC diagnosis vs other methods

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

The combination of the targeted cancer vaccine galinpepimut-S plus nivolumab resulted in a median overall survival of 35.4 weeks in patients with macroscopic deposits of malignant pleural mesothelioma who had received treatment for at least 1 month.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.

The FDA has granted a breakthrough therapy designation to adagrasib for use as a potential therapeutic option for patients with KRAS G12C–mutated non–small cell lung cancer following previous systemic therapy.

The Chinese National Medical Products Administration has granted conditional approval to olaparib for use as a monotherapy in the treatment in adult patients with germline or somatic BRCA-mutated, metastatic castration-resistant prostate cancer who have progressed after previous treatment that included a new hormonal agent like abiraterone acetate or enzalutamide.

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

The anti-TIGIT agent domvanalimab in combination with zimberelimab with or without etrumadenant demonstrated promising objective response rates when given as a first-line treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 expression of 50% or higher.

Key opinion leaders in lung cancer have a lively discussion on the challenges associated with making treatment decisions for patients with unresected stage III EGFR-mutated NSCLC.

A panel of thought leaders in the management of NSCLC review best practices for monitoring patients and making treatment decisions after adjuvant osimertinib.

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Savolitinib has been granted a conditional approval in China for use in patients with non–small cell lung cancer with MET exon 14 skipping alterations who experienced disease progression after previous systemic therapy or are unable to receive chemotherapy.

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.